SRC and cancer: When combined with dasatinib in MCF10A-WT and CDH1−/− cells, MK2206 exhibited synergy, indicating that the simultaneous targeting of SRC, DDR2 and AKT may be effective in specifically targeting E-cadherin-deficient cancer cells.